Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Annovis Bio, Inc.
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
August 06, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
July 24, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
July 16, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
July 09, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
July 02, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
June 27, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
June 26, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
June 25, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
June 18, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
June 11, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
June 05, 2024
From
Annovis Bio, Inc.
Via
GlobeNewswire
Annovis Bio Announces Pricing of $7.5 Million Public Offering
October 31, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces Launch of Proposed Public Offering
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
October 30, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
October 24, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
July 18, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Announces the Filing of a Groundbreaking Patent
June 27, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
June 20, 2023
From
Annovis Bio, Inc.
Via
Business Wire
Tickers
ANVS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.